Report
Oussema Denguir

Adocia : Adocia's rewriting its future

>€ 56m of cash at end-June - Adocia yesterday evening reported its H1 2018 figures, with sales of € 32.8m (vs € 19.4m in H1 2017) stemming mainly from the partnership agreement in China with Tonghua Dongbao ($ 50m upfront and $ 85m in milestones) for BC Lispro and BC Combo. Operating expenses increased to € 21.78m (+37% yoy), mainly as a result of legal costs (€ 3.8m) incurred in the case with Eli Lilly and an extra €2m in personnel expenses. Net profit came to € 10....
Underlying
Adocia SA

ADOCIA is a biotechnology company based in France. Co. specializes in the development of formulations for already-approved therapeutic proteins with a primary focus on insulins and treatments for diabetic foot ulcers. Co.'s biotherapy products are used in tissue regeneration and for treating chronic diseases. Co.'s proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins in areas such as wound Healing, diabetes, ulcers and monoclonal antibody creation. Co. also maintains activities in the formulation of monoclonal antibodies for the treatment of various chronic pathologies (oncology, inflammation, etc.).

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Oussema Denguir

Other Reports on these Companies
Other Reports from Oddo BHF
Matthias Desmarais
  • Matthias Desmarais

ResearchPool Subscriptions

Get the most out of your insights

Get in touch